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Abstract
Rapid progress has been made in the development of new diagnostic assays for tuberculosis in 
recent years. New technologies have been developed and assessed, and are now being 
implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of 
Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in 
December, 2010. This assay was specifically recommended for use as the initial diagnostic test for 
suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of 
countries with a high tuberculosis burden and half of countries with a high multidrug-resistant 
tuberculosis burden had incorporated the assay into their national tuberculosis programme 
guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark 
event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review 
the rapidly growing body of scientific literature and discuss the advantages and challenges of using 
the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects 
within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable 
and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics 
pipeline should remain a major priority for funders and researchers.
Introduction
The global burden of tuberculosis is unacceptably high (panel 1)1 and multidrug-resistant 
(MDR) tuberculosis is now a major health challenge worldwide. Of notified cases of 
pulmonary tuberculosis in 2011, an estimated 310 000 new cases were MDR, defined by 
active infection with Mycobacterium tuberculosis that is resistant to isoniazid and 
rifampicin.1 To eliminate tuberculosis as a public health problem by 2050, incidence will 
have to fall by an average of 16% per year for the next 40 years.2 Rates, however, are only 
declining at 2% per year.1 The scale of the disease burden is compounded by the intersection 
of the HIV and tuberculosis epidemics and by the global spread of MDR tuberculosis and 
extensively drug-resistant (XDR) tuberculosis (panel 1). Despite major efforts to increase 
case detection, an estimated third of new tuberculosis cases are still being missed each year, 
and the unavailability of a rapid, low-cost, accurate diagnostic assay that can be used at the 
point of care is a major hindrance.
Low-income and middle-income countries, which bear most of the global burden of 
tuberculosis, rely heavily on outdated tuberculosis diagnostic tests, including sputum smear 
microscopy, solid culture, and chest radiography. These tests do not have sufficient 
sensitivity or specificity, are too slow, or are not available at the periphery of the health 
system where patients first seek care. Opportunities to intervene early in the disease are 
therefore lost. Global capacity for drug susceptibility testing (DST) is inadequate and only 
9% of the estimated 630 000 prevalent cases of MDR tuberculosis worldwide in 2011 were 
diagnosed and notified.1,3
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For the past 5 years, the development of diagnostics for tuberculosis has progressed rapidly 
(figure).4 Old technologies have been reviewed and improved and new technologies have 
been developed, evaluated, and implemented. With a growing evidence base, WHO issued 
ten policy statements between 2007 and 2012 about tuberculosis diagnosis and diagnostic 
methods, which shows the progress that has been made. These policy statements address 
improvements in sputum smear microscopy,5-8 use of commercial and non-commerical 
culture-based systems for diagnosis and DST,9,10 and implementation of line-probe assays11 
for rapid molecular diagnosis of drug resistance. Negative recommendations were issued 
about the use of serodiagnostic tests and interferon-gamma release assays for diagnosis of 
tuberculosis or latent M tuberculosis infection in low-income and middle-income 
countries.12,13 After initial endorsement in December, 2010, WHO issued a policy statement 
in 2011, on the Xpert MTB/RIF automated molecular assay for rapid diagnosis of 
tuberculosis and detection of rifampicin resistance.14 Specifically, the assay was strongly 
recommended for use as the initial diagnostic test in individuals suspected of having MDR 
or HIV-associated tuberculosis.15 The assay was also conditionally recommended as a 
follow-on test to microscopy in settings where MDR tuberculosis and HIV-associated 
tuberculosis are less of a concern.
The development of the Xpert MTB/RIF assay is a landmark event in tuberculosis research, 
and this article summarises what is known about this assay, its assessment in different 
settings, and its implementation. Despite many compelling attributes of this new diagnostic 
test, the Xpert MTB/RIF assay is by no means the ideal test. We discuss the challenges 
associated with its use in resource-limited settings and review other important developments 
and future prospects within the diagnostics developmental pipeline.
Development of the Xpert MTB/RIF assay
The GeneXpert diagnostic system was originally developed by Cepheid (Sunnyvale, CA, 
USA) for rapid detection of anthrax,16 and was deployed for this purpose by the US Postal 
Service to permit rapid detection of mail contamination in sorting offices. It is a self-
contained, fully integrated, automated platform that can be used with minimal technical 
skills. The cartridge-based system incorporates microfluidics technology and fully 
automated nucleic acid analysis to purify, concentrate, detect, and identify targeted nucleic 
acid sequences from unprocessed clinical samples.17 An expanding range of different 
organisms can be detected with pathogen-specific cartridges within the same test platform, 
including enteroviral meningitis, meticillin-resistant Staphylococcus aureus, group B 
streptococcus, and influenza. The test platform is modular, with each module independently 
processing one cartridge at a time. Machines with one, two, four, 16, and 48 modules are 
available, permitting several assays to be run concurrently and independently. A high-
throughput machine is also available for centralised laboratories.
Rifampicin resistance is particularly amenable to rapid molecular detection because 95% of 
all rifampicin-resistant M tuberculosis strains contain mutations localised within the 81 bp 
core region of the bacterial RNA polymerase β subunit (rpoB) gene, which encodes the 
active site of the enzyme.18 Moreover, mutations that occur in this region are highly 
predictive of rifampicin resistance18,19 and the core region is flanked by M tuberculosis 
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complex-specific DNA sequences. Thus, M tuberculosis and rifampicin resistance can be 
tested simultaneously by targeting one amplicon generated with PCR technology. Moreover, 
rifampicin resistance is strongly, although not invariably, indicative of MDR tuberculosis.
The Xpert MTB/RIF assay uses molecular beacon technology20,21 to detect DNA sequences 
amplified in a heminested real-time-PCR assay. The assay uses single-use plastic cartridges 
with several chambers that are preloaded with liquid buffers and lyophilised reagent beads 
necessary for sample processing, DNA extraction, and PCR.22,23 Sample reagent included in 
the assay is designed to reduce the viability of M tuberculosis in sputum and reduce the 
biohazard risk.24 Subsequent processing is fully automated and results are available within 2 
h with less than 20 min of hands-on time.
Preclinical laboratory-based assessment
A thorough preclinical assessment of analytic performance and biosafety of the Xpert 
MTB/RIF assay was done.17 By spiking defined numbers of M tuberculosis bacilli into 
clinical sputum samples from patients without tuberculosis, the limit of detection (95% 
reliability for detection) of the assay was 131 colony forming units (cfu)/mL (95% CI 106–
176) of sputum.22 This result contrasts with the limit of detection of automated 
mycobacterial liquid culture, which is about 10–50 cfu/mL, and with that of smear 
microscopy, which is about 10 000 cfu/mL.25 Thus, the Xpert MTB/RIF assay has a 
sensitivity that is roughly two orders of magnitude greater than that of smear microscopy, is 
similar to solid culture, but is not quite as sensitive as liquid culture. The assay correctly 
identified genomic DNA from 79 phylogenetically and geographically diverse strains of M 
tuberculosis23 and no cross-reactivity occurred with a wide range of non-tuberculous 
mycobacteria or other organisms known to infect the respiratory tract.22,23 Further 
experiments showed that false-positive reactions due to laboratory cross-contamination with 
amplicons from the GenoType MTBDRplus assay (Hain Lifescience, Nehren, Germany) 
was very unlikely.23
Genomic DNA from several rifampicin-susceptible and rifampicin-resistant M tuberculosis 
isolates with diverse rpoB mutations were tested, and excellent accuracy for rifampicin 
resistance was reported.22,23 Further experiments were done in which DNA from resistant 
and susceptible strains were mixed in varying ratios to assess how this affected detection of 
rifampicin resistance.23 To enable detection, 65–100% of the DNA from the rifampicin-
resistant isolate had to be present, depending on the mutation.23 Overall, this finding 
suggests that in patients with mixed infections, the Xpert MTB/RIF assay might only detect 
the resistant strain if this strain is predominant. Moreover, subsequent selection of resistant 
strains during the course of standard tuberculosis treatment might lead to an apparent switch 
from a susceptible to a resistant phenotype when baseline testing is compared with repeat 
testing during treatment.
To assess biosafety requirements for the Xpert MTB/RIF assay, bioaerosol generation and 
bacterial viability studies were done. The viability of M tuberculosis was reduced by more 
than 8 logs within 15 min of incubation of sputum in sample reagent.22 Viable bioaerosols 
were not generated during the manual sputum processing with sample reagent or during 
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automated processing with the Xpert MTB/RIF assay, whereas infectious bioaerosols were 
generated during routine preparation of smears.24 These data therefore suggest that the 
Xpert MTB/RIF assay poses a substantially smaller biohazard risk compared with direct 
smear microscopy and, given adequate room ventilation, might reasonably be done without 
the need for special equipment such as biosafety cabinets, which are absent in most 
resource-limited settings.
Diagnostic accuracy of the Xpert MTB/RIF assay for pulmonary 
tuberculosis
Many studies in both high-income and resource-limited settings of the diagnostic accuracy 
of the Xpert MTB/RIF assay for pulmonary tuberculosis have been published.17,26 The 
multicountry assessment done by the Foundation for Innovative and New Diagnostics 
(FIND), published in 2010,27 enrolled 1730 patients suspected of having drug-sensitive or 
drug-resistant tuberculosis at five study sites in South Africa, Peru, Azerbaijan, and India. 
One direct test on sputum detected 551 (98·2%) of 561 patients with smear-positive 
tuberculosis and 124 (72·5%) of 171 patients with smear-negative tuberculosis.27 The test 
was specific in 604 (99·2%) of 609 patients without tuberculosis. In patients with smear-
negative tuberculosis, processing one, two, or three samples was associated with sensitivities 
of 72·5%, 85·1%, and 90·2%, respectively. These data formed a substantial part of the 
evidence base that led to the endorsement of the assay by WHO in 2010.15
A systematic review of studies published up to October, 2011, identified 18 studies 
containing 10 224 patients.26 15 reported on diagnosis of pulmonary tuberculosis, and the 
meta-analysis provided an overall pooled sensitivity of 90·4% (95% CI 89·2–91·4) and a 
pooled specificity of 98·4% (98·0–98·7). The pooled sensitivities for sputum smear-negative 
and smear-positive disease were 75·0% and 98·7%, respectively. Data published after this 
date have broadly similar findings. A modified G4 version of the cartridge was launched in 
December, 2011, and independent data on the diagnostic accuracy of this version are needed.
Data about the effect of implementation of Xpert MTB/RIF on clinical outcomes of patients 
investigated for tuberculosis are scarce. FIND did a multicentre assessment of 
implementation in South Africa, Uganda, Peru, India, Azerbaijan, and the Philippines.28 In 
all centres, the GeneXpert machines were located within laboratories at health facilities 
where smear microscopy was being done. The assay greatly accelerated the time to 
diagnosis, with a median time of 0 days compared with 1 day for smear microscopy, 16 days 
with liquid culture, and 20 days with solid culture.28 For patients with smear-negative 
tuberculosis, the Xpert MTB/RIF assay reduced the median time to start of treatment from 
56 days (IQR 39–81) to 5 days (2–8). Rates of untreated smear-negative culture-positive 
tuberculosis decreased from 39·3% without the Xpert MTB/RIF assay to 14·7% with the 
assay. Assay performance for detection of rifampicin resistance was also excellent, with a 
median time to detection of 1 day (IQR 0–1) compared with 20 days (10–26) with a line-
probe assay and 106 days (30–124) for phenotypic DST. Despite these promising results, 
they only come from one multicentre study. Furthermore, published data on the effect of the 
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Xpert MTB/RIF assay on clinical outcomes are not available. Operational research on the 
outcomes and effects of programmatic implementation efforts are urgently needed.
Molecular techniques that detect DNA from M tuberculosis detect both live and dead 
organisms and so might test positive by PCR despite being culture negative.29 A positive 
Xpert MTB/RIF assay result therefore does not imply viability of the organism and thus 
cannot be used to monitor response to treatment, treatment success, treatment failure, or 
relapse. Attempts are being made to develop a protocol whereby sputum samples are 
pretreated to prevent the DNA in non-viable organisms being amplified during PCR.30 
However, even if such an approach proved successful, it would be complex to implement. 
Alternative approaches being assessed include detection of RNA expression.
Diagnostic accuracy for extrapulmonary tuberculosis
The Xpert MTB/RIF assay was developed, optimised, assessed, and endorsed specifically 
for the detection of pulmonary tuberculosis using sputum. More recently, however, 
assessments of the assay have extended to various non-respiratory clinical samples from 
patients with extrapulmonary tuberculosis. Investigation for use in extrapulmonary 
tuberculosis is far more complex because of the diversity of clinical sample types, 
difficulties in obtaining adequate tissue for analyses, the challenge of providing a rigorous 
reference standard for comparison, and the range of ways to process samples before 
analysis.
Table 1 summarises data from studies of the diagnostic accuracy of the Xpert MTB/RIF 
assay that included a wide range of different samples from extrapulmonary sites. The 
reported sensitivity of the assay for extrapulmonary tuberculosis was highly heterogeneous, 
ranging from 25·0% to 96·6%, but exceeded 50·0% in all but one study (table 1). The 
heterogeneity between studies might be a result of the differences between patient 
populations, patient selection, type of extrapulmonary tuberculosis, the quality of samples, 
differences in sample processing, and the diagnostic reference standard used. The median 
sensitivity of these nine studies was 77·3% (range 25·0–96·6), consistent with a meta-
analysis of the few studies published before October, 2011, which reported a pooled 
sensitivity of 80·4% (95% CI 75·0–85·1).26
The two largest studies in table 1 reported that the sensitivity of the Xpert MTB/RIF assay 
was much higher for smear-positive than for smear-negative extrapulmonary tuberculosis 
samples.37,39 Overall, sensitivities exceeded 70% for tissue biopsy samples, fine needle 
aspirates, pus samples, gastric aspirates, and urine. However, reported sensitivities on small 
numbers of CSF samples differed substantially.37,39 Lower sensitivity has been noted when 
testing pleural, pericardial, peritoneal, and synovial fluid samples.33,39 Increasing evidence 
from diagnostic accuracy studies might, in the future, open the possibility for international 
recommendations for use of the assay for diagnosis of extrapulmonary tuberculosis.
Diagnostic accuracy in children
Microbiological confirmation of tuberculosis is possible only in a small minority of the 
children treated for the disease, and the time to diagnosis by culture is often prolonged. 
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Table 2 summarises data from five studies on the use of the Xpert MTB/RIF assay to 
diagnose pulmonary and extrapulmonary tuberculosis in children. Using culture as the 
reference standard, four of these studies reported that the sensitivity of the Xpert MTB/RIF 
assay for pulmonary tuberculosis was about two to three times higher than that of smear 
microscopy when testing induced sputum, nasopharyngeal aspirates, and gastric aspirate 
lavages.42-45 Sensitivity ranged between 65·1% and 75·9% and specificity was 98·8–100%. 
Two of the studies reported a high incremental yield (27·8%42 and 20%43) from testing a 
second sample. When analysing samples from a wide range of extrapulmonary sites from 
children, the Xpert MTB/RIF assay generated a substantial diagnostic yield (table 2).39 
Thus, although most disease in children is still clinically diagnosed, the Xpert MTB/RIF 
assay increases the proportion with laboratory confirmation compared with smear 
microscopy and greatly accelerates diagnosis compared with culture. Studies in progress are 
assessing the use of the Xpert MTB/RIF assay on non-respiratory samples such as stool,46 
urine, and CSF. The WHO and Global Laboratory Initiative is planning to revise policy for 
use of the Xpert MTB/RIF assay for childhood tuberculosis diagnosis (and diagnosis of 
extrapulmonary tuberculosis).
Diagnostic accuracy in people living with HIV
Diagnosis of HIV-associated tuberculosis is a huge challenge.47,48 Table 3 summarises seven 
studies of patients infected with HIV, comparing the sensitivity of sputum microscopy and 
the Xpert MTB/RIF assay with culture as the reference standard. The median sensitivity of 
smear microscopy was 52·8% (range 22·2–68·9) compared with 84·0% (58·3–91·7) with the 
Xpert MTB/RIF assay. In all seven studies, the sensitivity of the Xpert MTB/RIF assay 
exceeded that of microscopy with a median increment of 30·0% (range 17·4–37·8). The 
overall sensitivity of the Xpert MTB/RIF assay for HIV-associated tuberculosis was very 
heterogeneous (range 58·3–91·7%) and is likely to be a result of patient selection. The 
lowest sensitivity was in a study in which patients were actively screened for tuberculosis, 
irrespective of symptoms, and subanalysis showed that the sensitivity was very high in 
patients who had a cough for 2 weeks or longer.51 Overall, sensitivities were higher in 
studies of outpatients with chronic symptoms and higher still in studies of patients admitted 
to hospital (table 3). Thus, the sensitivity of the Xpert MTB/RIF assay relates to severity of 
symptoms, which in turn might reflect mycobacterial load.
Although the sensitivity of smear microscopy is substantially lower in patients with HIV 
than in uninfected patients,47,48 such an association is unclear for the Xpert MTB/RIF assay. 
Of the three studies with relevant comparative data28,49,52 (table 3), two28,49 studied 
outpatients and reported that sensitivity was roughly 10% lower in patients with HIV than in 
those without HIV. However, results of the third study,52 of inpatients, showed the converse. 
Importantly, the subset of patients with HIV with culture-positive but Xpert MTB/RIF assay-
negative disease have far more favourable prognostic characteristics and a lower risk of 
death than do those testing positive with the Xpert MTB/RIF assay.55
Two studies describe the usefulness of the Xpert MTB/RIF assay to diagnose HIV-associated 
tuberculosis through urine sample testing (table 1).40,41 Despite only small volumes of urine 
being tested, the yield of HIV-associated tuberculosis was substantial, with positive results in 
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samples from 44·4% of outpatients with culture-positive pulmonary tuberculosis and CD4 
cell counts of fewer than 50 cells/μL and 47·8% of inpatients with tuberculosis. Lower CD4 
cell counts were strongly associated with higher yield40 and yield was also increased when 
larger volumes of urine were concentrated by centrifugation.41 This might represent an 
important alternative diagnostic modality for the sickest patients with HIV-associated 
tuberculosis, especially those who cannot produce sputum samples. Studies are needed to 
assess the effect of the new diagnostic on different populations, including those in which 
treatment is frequently started presumptively on the basis of clinical assessment.
Xpert MTB/RIF assay for active pulmonary tuberculosis case finding
In addition to screening for tuberculosis before antiretroviral therapy,51 use of the Xpert 
MTB/RIF assay for active case finding is being explored in other clinical populations. This 
assay might enable active tuberculosis screening to be done within antenatal clinics in high 
tuberculosis burden settings,56 for example, although data are awaited. If this assay was 
done at point-of-care, screening could be much more readily integrated into the antenatal 
care pathway. The Xpert MTB/RIF assay has also been used successfully in a small pilot 
study of active case finding in household contacts of smear-positive index cases in 
Tanzania.57 In a large tuberculosis prevalence survey in a South African gold mine,58 the 
sensitivity was substantially higher than that of smear microscopy, but much lower (62·6%, 
95% CI 55·2–69·5) than that of the liquid culture reference standard, which is consistent 
with the findings of active case finding in an antiretroviral treatment clinic.51 Disadvantages 
of the Xpert MTB/RIF assay in the prevalence survey were that it tested positive in a subset 
of patients currently or previously treated for tuberculosis and was also more expensive per 
test than smear microscopy and liquid culture combined, although this excess cost might be 
offset by recent cartridge price reductions and by the advantage of test simplicity.58
Rifampicin resistance
Despite the first large-scale multicountry assessment of the Xpert MTB/RIF assay by FIND 
reporting high specificity for detection of rifampicin resistance,27 several subsequent studies 
have reported cases of confirmed false-positive rifampicin resistance detected with the 
original version of the assay.50,51,59-61 Although absolute numbers of such cases have been 
quite small, this drawback is a substantial problem for clinical decision making in settings 
where the prevalence of rifampicin resistance is low and the positive predictive value for 
rifampicin resistance is therefore poor. Where resistance is present in more than 15% of 
isolates, the positive predictive value is estimated to be more than 90%, but where the 
prevalence is under 5%, the positive predictive value might be less than 70%.62 Moreover, 
although the Xpert MTB/RIF assay seems to provide a high sensitivity initial screen for 
MDR tuberculosis, data from 14 supranational tuberculosis reference laboratories show that 
0·5–11·6% of rifampicin-resistant strains are sensitive to isoniazid, with marked regional 
variation.63 WHO has recommended that patients with rifampicin-resistant results should 
receive an MDR tuberculosis treatment regimen pending additional culture-based 
investigation and DST for first-line and second-line drugs.62
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In addition to false-positive rifampicin resistance results, a few studies reported a high rate 
of inconclusive results. In 2011, the manufacturers did a root cause analysis of these 
problems, and software and reagent changes have subsequently been made to the cartridges, 
including the redesign of probe B. The new software and cartridge combination, called G4, 
has undergone analytic laboratory assessment, and was launched in December, 2011.64 Early 
reports from South Africa suggest that the concordance with the rifampicin resistance results 
of line-probe assays is improved and that inconclusive results are decreased using the G4 
cartridges,65 but more solid evidence is awaited.
Costs and cost-effectiveness
The high cost of this technology (similar to that of liquid culture, but far exceeding that of 
smear microscopy) is seen as a key hurdle to implementation.66,67 FIND negotiated a 
discounted pricing structure applicable to 145 high burden and developing countries.68 A 
four module GeneXpert platform and linked computer costs about US$17 000 (more than 
60% lower than elsewhere). Compared with cartridge costs of roughly $65 in the European 
Union, discounted costs were initially $18·68 per cartridge when first endorsed by WHO.69 
Costs have since fallen, and with funding from the President’s Emergency Plan For AIDS 
Relief, US Agency for International Development, UNITAID, and the Bill & Melinda Gates 
Foundation, the cost per cartridge was set at $9·98 from Aug 6, 2012, for the next 10 
years.68
Initial analyses of the use of the Xpert MTB/RIF assay in countries with a high burden of 
tuberculosis suggest that this technology is likely to be a highly cost-effective method of 
tuberculosis diagnosis,70-72 although this will of course be setting specific. Cost-
effectiveness does not denote affordability, however, and in the poorest countries of the 
world with a high tuberculosis burden, the total yearly expenditure per head on health might 
be little more than $10–20. Moreover, neither the true costs of implementation nor the 
overall benefits are known. In South Africa, for example, the national scale-up of the Xpert 
MTB/RIF assay is estimated to be associated with a 53–57% increase in the yearly cost of 
the tuberculosis diagnostic programme.73 These costs would also vary depending on 
whether GeneXpert machines were placed only in existing microscopy laboratories or were 
extended to all facilities providing tuberculosis treatment, which could increase the budget 
by more than 50%.74 Moreover, increased overall case detection and diagnosis of MDR 
tuberculosis are estimated to increase the treatment programme costs by 34–37%.73 
Conversely, the potential benefits from reduced morbidity, mortality, and disease 
transmission associated with appropriate delivery of tuberculosis treatment and lower rates 
of inappropriate therapy have yet to be defined. In South Africa, only about half of notified 
tuberculosis cases are microbiologically confirmed, and whether implementation of the 
Xpert MTB/RIF assay will increase the overall number of tuberculosis diagnoses or simply 
increase the proportion of cases with microbiological confirmation is unknown. Further cost-
effectiveness analyses using data generated during scale-up in the field will be essential.
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Implementation and scale-up of the Xpert MTB/RIF assay
WHO policy guidance on the Xpert MTB/RIF assay has been incorporated into national 
guidelines by a third of reporting countries.1 Two-thirds of high tuberculosis burden 
countries and a half of high MDR tuberculosis burden countries have already incorporated 
the assay into their revised diagnostic policies. Up to the end of June, 2012, 1·1 million test 
cartridges were procured by 67 (46%) of the 145 countries eligible to purchase them at 
FIND-negotiated concessional prices.1,4 Scale-up is expected to be substantially accelerated 
by the reduction in cartridge costs announced in August, 2012.68
WHO endorsement of the Xpert MTB/RIF assay has resulted in rapid donor and partner-
driven infusions of GeneXpert machines and cartridges into countries. Although this 
unprecedented support of tuberculosis diagnostic implementation should be encouraged, 
maximising the effects and long-term sustainability of the Xpert MTB/RIF assay will 
probably prove to be dependent on national ministry of health leadership, strategic planning, 
coordination of technical partners and donors, and continuous monitoring and assessment. 
Large-scale implementation will invariably need revision of national algorithms, policies, 
registers, request forms, and monitoring and assessment methods. Thus, ministries of health 
are encouraged to take a step-wise approach to introduction and scale-up, beginning with the 
establishment of an in-country coordination mechanism, such as an Xpert MTB/RIF assay 
technical working group or advisory team. Such working groups should include 
representation from all key stakeholders, including national tuberculosis and AIDS control 
programmes, national public health laboratories and supranational tuberculosis reference 
laboratories, implementing partners, and donors and should be tasked with leading the 
strategic planning, implementation, and assessment processes. Implementation plans should 
consider the local epidemiology, available diagnostic services and laboratory systems, and 
first-line and second-line drug treatment capacity. Moreover, implementation should be in 
line with relevant strategic plans (eg, national tuberculosis and AIDS control programmes 
and national laboratory strategic plans). Furthermore, implementation should be closely 
linked to monitoring and assessment of clearly defined outcome measures to inform 
revisions in procedures, policies, and plans.
South Africa has led the way with national implementation of the Xpert MTB/RIF assay. 
The South African Ministry of Health has recommended replacement of smear microscopy 
as the initial diagnostic test for tuberculosis. This step is unlikely to be taken by other 
countries in the region in the foreseeable future because of cost and logistical constraints. As 
of June, 2012, South Africa accounted for 37% of the modules and 53% of the cartridges 
procured globally.1 In March, 2011, the National Department of Health announced the plan 
to achieve national scale-up over 2–3 years. The South African National Health Laboratory 
Service launched a pilot programme, placing GeneXpert platforms in 25 smear microscopy 
centres across the country with throughputs ranging from 16 to more than 400 tests per 
day.73 Following this successful pilot, machines are now being placed in all existing smear 
microscopy laboratories, fully replacing smear microscopy for diagnosis of pulmonary 
tuberculosis in South Africa.73 Embedded research studies and monitoring and assessment 
are likely to yield invaluable data that will increase the understanding of how best to 
implement this assay.
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Challenges associated with implementation
Panel 2 summarises the key strengths and weaknesses of the Xpert MTB/RIF assay and 
panel 3 summarises the potential benefits as well as the challenges of Xpert MTB/RIF assay 
implementation for routine use in resource-limited settings.66,75 Increased diagnosis of drug-
sensitive tuberculosis and MDR tuberculosis should be matched by expanded capacity to 
effectively treat these cases, including a scale-up in quality MDR tuberculosis treatment 
facilities and trained staff. Rigorous quality assessment programmes will also be needed, 
following, for example, a model developed in South Africa that used dried culture spots of 
inactivated M tuberculosis on filter paper.76 This is essential to ensure that results are 
accurate.
Despite being relatively simple, implementation of the Xpert MTB/RIF assay in resource-
limited settings has needed investments in training of operators and laboratory staff. The 
computer interface has been more challenging than expected for operators in some countries 
and additional training has been needed. This issue should be taken into consideration by 
continuing efforts aimed at development of nucleic acid amplification-based platforms for 
implementation in more decentralised facilities. Cartridges have to be stored at 2–28°C, 
which might be difficult in hot climates where transportation is difficult and lengthy and 
where a cold chain is not available.
A further challenge is the feasibility of deploying the assay at the point-of-care. Centralised 
location has been associated with failures to link results to patients to inform treatment in a 
timely manner, undermining outcomes.77 By contrast, use of the assay at the district and 
subdistrict levels resulted in a substantial increase in treatment uptake in the FIND 
implementation study.28 Location and use within tuberculosis treatment facilities adds 
further challenges. In South Africa, for example, laboratory placement would need 274 
instruments, whereas location at points of treatment would require 4020 instruments with a 
51% increase in cost ($107 million per year).74 Moreover, results of operational research 
into point-of-care implementation showed that the turnaround time for sample processing 
was often more than 2 h and that failure to link results to patients on the same day was an 
unforeseen difficulty.78 A faster assay would be a substantial advantage in this respect. 
Taking a patient through the whole process of obtaining samples, running the Xpert 
MTB/RIF assay test, linking results back to the patient, and starting tuberculosis treatment 
on the same day needed a substantial increase in human resource requirements in the clinic, 
such that the equivalent of an additional 2·5 staff were needed to manage 16 patients per day 
suspected of tuberculosis.78 Use of the assay in the clinic was also associated with increased 
management responsibilities. Nevertheless, this was offset by increased case detection with 
same-day treatment initiation in more than 80% of new cases, a corresponding increase in 
enthusiasm and morale of clinic staff, and reduced laboratory requirements.
Other advances in tuberculosis diagnostic tests
Further developments in nucleic acid amplification test (NAAT) technology are promising.4 
A simplified manual NAAT using loop-mediated isothermal amplification with a simple 
visual colorimetric read-out is being assessed for use in peripheral laboratory facilities in 
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resource-limited settings.4,79 However, fully automated systems that use isothermal 
amplification and operate at lower temperatures could potentially be used outside the 
laboratory environment.4,80 Hand-held systems the size of a smartphone produce PCR 
product more rapidly and have much lower power needs than does GeneXpert, permitting 
battery operation. Identification of resistance mutations to several key drugs with 
multiplexed assays might greatly reduce the need for follow-on DST. Thus, several fully 
automated assays that compete with the Xpert MTB/RIF assay and that will be more 
applicable for point-of-care are likely to be developed in the future.4 However, how the 
donor assistance that has heavily subsidised the implementation of Xpert MTB/RIF in 
resource-limited settings will affect the development and entry of newer diagnostic assays to 
the marketplace is not clear. Commercially, funding is not a level playing field. Moreover, 
the up-front costs of doing field assessment trials needed to gain regulatory approval and 
WHO endorsement are substantial and might be prohibitive for small companies. 
Furthermore, the prospect of the emergence of cheaper rapid tests more applicable at the 
periphery (community level) poses an interesting dilemma as to whether investment should 
be made in current more costly technology, or whether it might be better to wait for the next 
generation of tests to become available.
A promising development is a point-of-care immunochromatographic (dip-stick) assay that 
detects mycobacterial lipoarabinomannan in urine.81-83 The specific niche for this assay 
seems limited to the diagnosis of HIV-associated tuberculosis in patients with advanced 
immunodeficiency (CD4 cell counts <200 cells/μL), such as those being screened in 
antiretroviral treatment clinics or medical inpatients with HIV.81,84-86 Studies from South 
Africa have reported that in patients with the lowest CD4 cell counts, the assay can 
potentially diagnose around two-thirds of cases with high specificity within 30 min.83 
Patients whose tuberculosis is detected by this assay are the subset who are likely to have 
disseminated tuberculosis, have the highest mortality risk,87,88 and are most likely to benefit 
from same-day initiation of tuberculosis treatment. More data on standardisation of test 
production by the manufacturer and on diagnostic accuracy in well conducted studies in 
different settings are needed, as are studies of clinical effect.
Other systems such as breathalysers that detect M tuberculosis-specific antigens89 and so-
called electronic noses that detect volatile biomarkers using chemical sensors and pattern 
recognition systems90,91 are being explored. Meanwhile, in the present postgenomics era, 
the diagnostics developmental pathway should continue to be fuelled by basic research and 
development to identify biomarkers that can serve as new specific targets for diagnostic 
assays.92
Future prospects for point-of-care diagnosis
The ideal test for tuberculosis will be a true point-of-care assay that enables accurate 
diagnosis of tuberculosis and detection of drug resistance within the time of a clinic 
consultation, and one that can be implemented at all levels of the health system for adults 
and children, with and without HIV.93 Although the Xpert MTB/RIF assay undoubtedly 
represents an important breakthrough and step forward towards this ideal, its high relative 
cost, sophisticated hardware, and constraints for point-of-care use will undoubtedly restrict 
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its implementation. Future advances in molecular diagnostics should build on this success 
and tackle these remaining challenges.94 Despite recent developments in nucleic acid 
amplification-based diagnostics and related technological platforms, the tuberculosis 
diagnostic pipeline is nevertheless weak and should be strengthened. The need for a better 
test for paediatric tuberculosis diagnosis is largely unmet because there is no evidence to 
suggest that the Xpert MTB/RIF assay will have a major effect on tuberculosis diagnosis in 
this group.
Conclusions
The emergence of the Xpert MTB/RIF assay represents a major step forward in tuberculosis 
diagnostics. Although this assay is not perfect, the advantages offered in settings with high 
disease burdens and high rates of drug-resistant and HIV-associated tuberculosis convinced a 
country such as South Africa to adopt this technology as the initial diagnostic test for 
pulmonary tuberculosis. More wide-scale implementation of the Xpert MTB/RIF assay will 
provide data on clinical effect and programmatic outcomes so that the true cost-effectiveness 
of the assay can be assessed. Rapid developments in nucleic acid amplification technology 
are fuelling the emergence of further fully automated systems that might be more readily 
implementable at the point of care. However, a rapid, accurate, and affordable diagnostic test 
for tuberculosis that can be easily implemented is urgently needed. Greater investment in the 
developmental pipeline for tuberculosis diagnostics remains a priority for funders and 
developers.
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• The Xpert MTB/RIF assay is a landmark development in tuberculosis 
diagnostics and yet it does not fulfil requirements as a point-of-care assay
• One Xpert MTB/RIF test on sputum detects 90% of pulmonary tuberculosis 
(99% of smear-positive disease and about 75% of smear-negative disease)
• High sensitivity of Xpert MTB/RIF for rifampicin resistance is accompanied by 
some false-positive results (which might be reduced by the new G4 version of 
the assay) and confirmatory drug sensitivity testing is needed
• Despite substantial price discounting and relative simplicity of use, 
implementation of the Xpert MTB/RIF assay is hindered by several factors
• Studies of clinical and programmatic effects and associated cost-effectiveness of 
the Xpert MTB/RIF assay are needed
• Greater funding for research and development for a simple, low-cost, accurate 
point-of-care assay is needed
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The estimated global burden of tuberculosis in 20111
8·7 million incident cases
• 1·1 million (13%) cases in people living with HIV
• 490 000 cases in children younger than 15 years
1·4 million deaths
• 990 000 HIV-seronegative people
• 430 000 (31%) HIV-seropositive people
• 500 000 (36%) women
• 64 000 children younger than 15 years
Multidrug-resistant cases
• 630 000 prevalent cases
• 310 000 incident cases
• 3·7% of new incident cases
• 20% of previously treated incident cases
• 9% of multidrug-resistant cases are extensively drug-resistant
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Key strengths and weaknesses of the Xpert MTB/RIF assay
Strengths
• Robust
• Good accuracy for tuberculosis diagnosis
• Simple to use
• Rapid (2 h) compared with existing tests
• Detects both Mycobacterium tuberculosis complex and rifampicin resistance
• Better sensitivity and specificity than smear microscopy
• Does not need advanced biosafety equipment
• Closed system with low risk of cross-contamination
• Could potentially be used to test a broad range of samples from extrapulmonary 
sites—eg, lymph node aspirates, gastric lavage, urine, and CSF (not yet 
endorsed by WHO; more data awaited)
• GeneXpert platform is multifunctional and could be used for other diagnostics 
such as HIV viral load
• Modular platform permits capacity to match demand in a given facility
• Operators do not need formal laboratory training
Weaknesses
• Expensive
• Sophisticated hardware needing calibration and maintenance and linkage to a 
computer and secured premises
• Operators need training in basic computer skills
• Needs continuous electrical power supply and air conditioning
• Storage of samples at room temperature restricted to 3 days
• Relatively short shelf life of reagent cartridges needing good procurement 
systems
• Need for cartridge storage at 2–28°C and system for disposal after use
• Although comparatively rapid, the turnaround time is a challenge for same-day 
diagnosis and treatment in overcrowded health facilities
• False-positive rifampicin resistance results
• Cannot differentiate between live and dead M tuberculosis, thus cannot be used 
to monitor treatment success or failure, or relapse
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• Cannot differentiate between M tuberculosis, M bovis, and BCG vaccine
• Use with extrapulmonary samples is not yet fully defined
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Use of Xpert MTB/RIF assay as the initial diagnostic test for tuberculosis in 
resource-limited settings
Anticipated benefits
• Increase in tuberculosis case detection, especially of smear-negative disease
• Reduction in time to diagnosis and treatment
• Reduced patient default during investigation for tuberculosis, increasing uptake 
of tuberculosis treatment
• Reduced morbidity, mortality, and tuberculosis transmission
• Increased detection and treatment of multidrug-resistant tuberculosis
• Increased morale of health-care workers in tuberculosis services
• Reduced need for culture
• Reduced biohazard
• Reduced presumptive prescribing of tuberculosis treatment
Challenges
• Increase in budget needed for tuberculosis diagnostics
• Additional testing for drug resistance needed for those testing positive for 
rifampicin resistance
• Use of the assay in centralised laboratories might blunt the potential effect of 
this near-patient technology
• Use of outside laboratories might be associated with increased human resource 
needs and administrative responsibilities in clinics
• Rapid diagnosis has to be translated into more rapid treatment initiation, which 
is challenging in some settings
• Increased diagnostic capacity should be matched by increases in treatment 
capacity for drug sensitive and multidrug-resistant tuberculosis
• Diagnostic algorithms, notification systems, and methods for monitoring and 
assessment need to be redefined
• Restricted operating temperature range
• Need for a stable electricity supply
• Instruments and associated computers might break down or be stolen
• Need for external quality assurance and yearly calibration of instruments
• Need for robust supply chains and storage facilities for bulky cartridges with 
short shelf-life
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Search strategy and selection criteria
We searched PubMed and Google Scholar (Jan 1, 1995, to Dec 24, 2012), the Cochrane 
library (Jan 1, 2001, to Dec 24, 2012), and Embase (Jan 1, 2001, to Dec 24, 2012) for 
reports published in English with the terms “tuberculosis”, “Mycobacterium 
tuberculosis”, “TB diagnostic tests”, “TB diagnosis”, “clinical trials”, “Xpert MTB/RIF 
assay”, “GeneXpert”, “Cepheid”, “accuracy”, “sensitivity”, and “specificity”. We also 
searched the website of the STOP TB Partnership’s New Diagnostic Working Group. We 
reviewed studies cited by articles identified by this search strategy and selected those we 
identified as relevant.
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Figure. Development pipeline for new tuberculosis diagnostics
Reference level laboratories refer to national level facilities. Intermediate level laboratories 
refer to district and subdistrict level facilities. Peripheral level laboratories refer to 
community level facilities. Reproduced from WHO’s global tuberculosis control report, 
2012,1 by permission of the World Health Organization. Ab=antibody. Ag=antigen. 
CRI=colorimetric redox indicator assay. DST=drug susceptibility test. LED=light emitting 
diode. LPA=line-probe assay. MDR-TB=multidrug-resistant tuberculosis. 
MODS=microscopic observation drug susceptibility. NAAT=nucleic acid amplification tests. 
NRA=nitrate reductase assay. SS+=sputum smear-positive. VOC=volatile organic 
compound. XDR-TB=extensively drug-resistant tuberculosis.
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Table 1















































Culture (solid and 
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media)












Culture (solid and 
liquid
media)









positive cytology + 
acid-fast
bacilli and/or culture 
of TB
96·6% (86·6–100) 88·9% (69·6–100)
Moure et 
al, 201236








Culture (solid and 
liquid
media)
58·3% (48·5–67·8) 100% (91·4–100)
Vadwai et 
al, 201137
India 283 250 Tissue biopsy 
samples (105), 
pus






80·6% (75·5–85·0) 99·6% (97·8–100)
Zeka et al, 
201138
Turkey 48 128 Pleural fluid, 
lymph node 
biopsy,
CSF, urine, skin 
biopsy samples,
pericardial fluid





54·2% (40·3–67·4) 100% (97·2–100)
Tortoli et 
al, 201239







CSF (14), urine 
(16), peritoneal,






positive response to 
TB
treatment
81·3% (76·2–85·8) 99·8% (99·4–100)







































Testing of urine samples from patients infected with HIV with culture-positive pulmonary TB
Lawn et 
al, 201240



























Only studies with at least 20 reference standard diagnoses of extrapulmonary tuberculosis were included. TB=tuberculosis. MTB=Mycobacterium 
tuberculosis. RIF=rifampicin. NA=not applicable.
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Table 2
Studies of the Xpert MTB/RIF assay for diagnosis of tuberculosis in children





Prospective study of inpatients (n=452) with median age 19 months (maximum
15 years) and suspected TB: from two induced sputum samples, the Xpert MTB/
RIF assay diagnosed 75·9% (44 of 58) of culture-positive cases (specificity 98·8%)
compared with 37·9% using smear microscopy; in smear-negative cases, the
incremental yield of the second Xpert MTB/RIF test was 27·8%
Rachow
et al, 201243
Tanzania Prospective study of 164 children aged <14 years (median 5·8 years): of
28 microbiologically confirmed cases, the Xpert MTB/RIF assay diagnosed 100%
(7 of 7) smear-positive cases and 66·6% (14 of 21) smear-negative cases with
100% specificity; the incremental yields of testing second and third samples were





Prospective study of inpatients (n=535) with median age 19 months (maximum
15 years) and suspected TB: the yield of two Xpert MTB/RIF assay tests on
nasopharyngeal aspirates from culture-confirmed cases was 65% (41 of 63)
compared with 33% (21 of 63) by smear microscopy
Bates et al,
201345
Zambia Prospective study of inpatients (n=930) with median age 24 months (maximum
15 years) and suspected TB: in culture-positive cases (n=58), the Xpert MTB/RIF
assay was more sensitive than smear microscopy when testing sputum samples




Italy Study of the diagnosis of extrapulmonary TB in adults and children with a wide
range of different sample types (tissue biopsies, pleural fluid, gastric aspirates, pus,
CSF, and urine) that used a composite reference standard of culture, radiology,
histology, and treatment response: the sensitivity in samples from children
(86·9%) tended to be higher than that in samples from adults (77·6%), possibly as
a result of the types of clinical samples in each group
TB=tuberculosis. MTB=Mycobacterium tuberculosis. RIF=rifampicin.
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Table 3
Studies assessing the diagnostic accuracy of the Xpert MTB/RIF assay compared with 
culture in patients with HIV investigated for pulmonary tuberculosis
Country Clinical population Patient selection Sensitivity of smear















































South Africa Outpatients (mostly HIV+)
with suspected TB with
cough for ≥2 weeks
Presentation with 
suspected TB
with cough ≥2 
weeks
HIV+: 54% (38–69) HIV+: 84% (69–93)
Lawn et al,
201151
South Africa Outpatients (HIV+) 
enrolling











HIV+: 22·2% (13·3–33·6) HIV+: 58·3% (46·1–69·8)
Studies of hospital inpatients
O’Grady et al,
201252
Zambia Hospital medical inpatient
admissions (HIV+ and 
HIV−)





















HIV+: 66·7% (39·1–86·2) HIV+: 91·7% (64·6–98·5)
Carriquiry et al,
201254










HIV+: 68·9% (54·3–80·6) HIV+: 86·3% (74·3–93·2)
TB=tuberculosis. MTB=Mycobacterium tuberculosis. RIF=rifampicin.
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